Sequential HIV Env Immunization for Germline B Cell Maturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing immunization strategies fail to effectively elicit broadly neutralizing antibodies against HIV due to the inability of engineered HIV envelope proteins to engage germline B cells and overcome steric constraints imposed by N-linked glycosylation sites, particularly at position 276, preventing the maturation of antibodies capable of neutralizing the virus.
Innovation Solution
A sequential immunization strategy involving an engineered HIV envelope protein that stimulates germline B cells, followed by a glycosylated N276 HIV Env protein, without intervening immunogens, guides the maturation of antibodies against HIV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If engineered HIV envelope proteins are used for immunization, then B cell activation is improved, but antibody maturation is blocked due to steric constraints from N-linked glycosylation sites
Solution Approach 1:
The patent removes specific N-linked glycosylation sites (particularly at position 276) from the HIV envelope protein immunogen. This extraction of the glycosylation site eliminates the steric constraint that blocks antibody maturation, while preserving the protein's ability to activate B cells. The removed glycan structure was the harmful element preventing the development of neutralizing antibodies.
Solution Approach 2:
The patent applies local quality modification by selectively altering specific regions of the HIV envelope protein while maintaining other regions unchanged. Specifically, glycosylation sites at positions 276, 460, and 463 are removed or modified, while the overall protein structure and B cell epitopes are preserved. This localized modification allows B cell activation to continue while enabling antibody maturation that was previously blocked.
2Productivity
If germline B cells are engaged by immunization, then immune response initiation is improved, but neutralizing antibody production is prevented by steric constraints
Solution Approach 1:
The patent extracts the blocking glycosylation site at position 276 from the HIV envelope protein. This removal eliminates the steric barrier that prevents germline B cells from maturing into neutralizing antibody producers. The B cells can now properly mature and produce neutralizing antibodies while the immunogen still effectively initiates the immune response through engagement of germline B cell receptors.
Solution Approach 2:
The patent changes the glycosylation status parameter of the HIV envelope protein by removing N-linked glycosylation sites. This parameter change from glycosylated to non-glycosylated at specific positions (276, 460, 463) transforms the protein's interaction with B cells, allowing both germline B cell engagement and subsequent maturation into neutralizing antibody producers to occur effectively.
3Stability of the object's composition
If N-linked glycosylation sites are present on HIV Env protein, then protein stability is improved, but antibody maturation is blocked by steric constraints
Solution Approach 1:
The patent removes specific N-linked glycosylation sites (at positions 276, 460, and 463) from the HIV envelope protein. This extraction eliminates the steric constraints that block antibody maturation. The protein maintains sufficient stability through its overall structure and remaining glycosylation sites, while the removed sites specifically were responsible for blocking B cell maturation without being essential for basic protein stability.
Data Source
AI summary
Sequential immunization strategies to guide the maturation of antibodies against the human immunodeficiency virus (HIV) are described. The sequential immunization strategies utilize an HIV envelope protein (Env) that binds germline (gl) B cells as a first (prime) immunization and an Env with a functional glycosylated N276 as a second (boost) immunization. The sequential immunization strategies successfully elicit neutralizing antibodies against HIV.